Ruti Aga: Six-Year Ban, a Forged Prescription and the Real Injury Inside the Marathon Economy

Ruti Aga's career did not end at a finish line. It ended at a prescription pad. The most important document in the Athletics Integrity Unit's Thursday statement was not a timing sheet but a forged medical prescription issued by a family member. Aga, 32, has been banned for six years from 10 September. The positive sample came after she won a half marathon in China in March. The arithmetic is simple: two years for presence, four for tampering. Two plus four equals six. The arithmetic is simple; the case is not. I have watched the 2026 Tokyo Marathon finish twice—once for the splits, once to understand how Aga managed her pace over the last ten kilometres. That day she won a Major. Three second-place finishes at World Marathon Majors followed. That baseline has to come first, because in this case the conversation about the sanction keeps running ahead of the conversation about performance. Aga was a 2:18 to 2:20 marathoner—elite, but not a natural global-championship medallist inside Ethiopia's current depth. Her name belongs in Major results, not in a medal table. A technical correction is necessary here. Several reports have called methylprednisolone a prohibited steroid. It is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List. Under the current rules, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. That means the case turns on route and timing, not on 'steroid use'. A therapeutic knee injection can be legal out of competition; it becomes a violation when residues are present inside the in-competition window. That technical point is the legal hinge of the entire case. Aga cited a knee injury. For a marathoner, that explanation is medically plausible—knee inflammation and chronic knee trouble are common in high-volume distance runners. But the prescription on which the defence rested was not real. According to the AIU, the prescription was issued by a family member who was not a registered doctor. He claimed to have used an old prescription pad from a former workplace. The clinic cited did not exist. The clinic explicitly disowned the pad. Three separate verification failures—the doctor's registration, the clinic's existence and the pad's authenticity. This is not a filing error; it is the signature of a system that was not there. The sanction architecture is standard. Two years for presence is consistent with a panel finding the violation proven without proven intent. Four years for tampering is the Code's standard sanction. Together they make six. The provisional suspension is dated 10 September, so the ban is backdated to it. That is procedural arithmetic, not a reduction. At 32, a six-year ban means a return at roughly 38. In Ethiopian women's marathon depth, a 38-year-old with a doping record is effectively unselectable. The ban is six years on paper; in career terms it is a lifetime. The real story here is less about the substance than about medical governance. An athlete with a credentialed team physician would either have obtained a Therapeutic Use Exemption for a knee injection or followed WADA's route-specific washout guidance. Neither appears to have happened. Instead, documents were manufactured for the defence. That is what makes this more than a doping case: it is an entourage failure. The appearance-fee economy in East African road running is strong. Between Majors, label races in China and Asia are a lucrative, low-risk income tier. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. The matrix said London was ready; I asked who wrote the matrix. Here the matrix is a prescription. The question is not who printed it. The question is why there was no system to treat it as medical evidence. The AIU's tampering charge rested not only on the document but on statements made in interview. That means the athlete was questioned, language and translation conditions existed, and a separate four-year sanction attached to that process. The point recurs in African road-running cases. It should be treated as part of the procedural audit, not as an excuse. There is a paradox in this case. There is no proven endurance benefit from glucocorticoids. Yet the six-year ban lands on a substance that is not an anabolic muscle-building agent. The sanction came from the forged paperwork, not from the pharmacological power of the drug. That is the most important lesson: anti-doping investigation is shifting from the sample to the document. The old question was what the sample contained. The new question is whether the paper filed in defence is real. That shift targets a road-running ecosystem where medical support is informal and agent-management roles are often blurred. Ethiopia's women's marathon will not visibly suffer. The depth is so extreme that removing one 2:18 to 2:20 athlete does not change national selection arithmetic. Aga's three Major second places were commercial-tier results, not global championship conversions. Do not read this as Ethiopian weakness. Read it as a layer of administrative risk. In several East African road-running cases, the first violation is the substance and the second charge is a fabricated or altered explanation. The pattern shows that the centre of sanctioning is no longer doping alone; it is the attempt to conceal doping. There is another layer: China's label-race market. Large appearance fees, deep East African elite fields and a growing AIU presence. That combination means integrity risk will stay attached to results at this tier. In road racing, the in-competition testing window opens at 23:59 the day before the race. An injection given days earlier can still be caught. That technical fact was fatal to Aga's defence. With genuine medical records, route and timing could have been argued. The forged prescription closed the one route that might have worked. In the verification room the truth arrived in frames; on the track it arrived in breath. That line fits this case directly. The sample result is one frame; the prescription check is another; the interview transcript is a third. Put together, they show an athlete who chose to alter paper instead of taking the correct route through injury. That choice is hers, but the system around her shares responsibility. Someone could have told her how a TUE works. Then perhaps the case would not have reached a tribunal. Two reactions will follow the six-year ban. One will say the AIU is rigorous, and that is good. The other will say the sanction level falls unequally on African road runners. There is some truth in both, and both simplify the issue. Rigour is visible in the fact that a two-year presence sanction was extended by a four-year tampering sanction. The inequality argument is visible in the fact that a glucocorticoid with no proven endurance benefit became a career-ending six-year ban. But that inequality comes from procedure, not from the substance. With genuine records, this sanction structure would not have existed. Protocol is memory written down—which is why institutions fear it. Here the protocol gap was not only with the athlete but with the entourage. Medical support does not mean an injection for every injury. It means a record for every injection, a clean route, timing away from competition and a TUE process when needed. In Ethiopian and Kenyan training clusters, that system remains informal. Agent, physio and 'doctor' roles overlap. Aga's case is a product of that overlap. Eleven weeks of phone calls taught me more than a season of press conferences. When the 2026 season collapsed, I logged the lockdown conditions of 43 Indian athletes—who had a track, who had a Railways job, who had stopped training. That exercise taught me that an athlete's career runs on medical and employment structures, not only on a stopwatch. In Aga's case, that structure broke. The knee was a real injury; the prescription was a false treatment; the six-year ban is the price of the falsehood. What comes next? More cases of this type may reach the AIU, because the same medical networks serve many athletes in the same training clusters. If agents and medical staff are brought inside a licensing framework, the next athlete may arrive with TUE paperwork instead of a forged prescription. If testing rises at label races, the appearance-fee arithmetic will change too. The question is what the sport is punishing—the injection or the paper. If the answer is the paper, Aga's case is a warning. If the answer is the injection, then the case shows that medical support in the marathon economy is still informal charity, not a right.